Acesso livre
Acesso livre

Infectologia

Análise sistemática | Variação na taxa de infecção-fatalidade da COVID-19 por idade, tempo e geografia durante a era pré-vacina.

8 Mar, 2022 | 16:19h

Variation in the COVID-19 infection–fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis – The Lancet

Comentário convidado: Understanding of COVID-19 from infection–fatality ratio – The Lancet

Quantificação dos efeitos da pandemia de COVID-19 sobre equidade de gênero nos indicadores de saúde, sociais e econômicos.

8 Mar, 2022 | 16:18h

Quantifying the effects of the COVID-19 pandemic on gender equality on health, social, and economic indicators: a comprehensive review of data from March, 2020, to September, 2021 – The Lancet

Comentários:

Gender equality and COVID-19: act now before it is too late – The Lancet

Social and economic effects of the COVID-19 pandemic threaten to reverse progress towards gender equality: study – The Lancet

 

Comentário no Twitter (fio – clique para saber mais)

 

M-A | Eficácia das vacinas contra Covid-19 em pacientes imunocomprometidos.

8 Mar, 2022 | 16:16h

Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis – The BMJ

Comunicado de imprensa: Study suggests additional covid-19 vaccine doses for immunocompromised patients – BMJ Newsroom

Conteúdos relacionados: Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review.

 

Comentário no Twitter

 

Diretriz atualizada da OMS recomenda condicionalmente o molnupiravir para pacientes com Covid-19 não grave sob alto risco de internação.

8 Mar, 2022 | 16:14h

Comunicado de imprensa BMJ: WHO recommends antiviral drug for patients with non-severe covid-19 at highest risk of hospital admission – BMJ

Comunicado de imprensa OMS: WHO updates its treatment guidelines to include molnupiravir

Ver diretriz atualizada: A living WHO guideline on drugs for covid-19 – BMJ

Conteúdos relacionados:

Editorial (recém-publicado): Molnupiravir’s authorisation was premature – The BMJ

RCT: Molnupiravir reduced the risk of hospitalization or death in at-risk (i.e., obesity, over 60 years, etc.) unvaccinated adults with Covid-19.

Merck’s COVID pill loses its luster: what that means for the pandemic – “Molnupiravir was initially heralded by public-health officials as a game-changer for COVID-19, but full clinical-trial data showed lower-than-expected efficacy”.

FDA panel narrowly recommends authorization of first antiviral pill to treat COVID.

[Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%.

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

Revisão | Estratégias terapêuticas para Pseudomonas aeruginosa multirresistente.

8 Mar, 2022 | 15:03h

Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa – Infectious Diseases and Therapy

Conteúdos relacionados:

IDSA guidance and ESCMID guidelines: complementary approaches toward a care standard for MDR Gram-negative infections – Clinical Microbiology and Infection

European guidelines for the treatment of infections caused by Multidrug-resistant Gram-negative bacilli.

IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.

Acinetobacter baumannii resistente a carbapeném: colonização, infecção e opções atuais de tratamento.

8 Mar, 2022 | 15:02h

Carbapenem-resistant Acinetobacter baumannii: Colonization, Infection and Current Treatment Options – Infectious Diseases and Therapy

Conteúdos relacionados:

IDSA guidance and ESCMID guidelines: complementary approaches toward a care standard for MDR Gram-negative infections – Clinical Microbiology and Infection

European guidelines for the treatment of infections caused by Multidrug-resistant Gram-negative bacilli.

IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.

OMS | Pandemia de COVID-19 desencadeou um aumento de 25% na prevalência de ansiedade e depressão ao redor do mundo.

3 Mar, 2022 | 16:55h

Comunicado de imprensa: COVID-19 pandemic triggers 25% increase in prevalence of anxiety and depression worldwide – World Health Organization

Resumo científico: Mental health and COVID-19: Early evidence of the pandemic’s impact – World Health Organization

 

Comentário no Twitter (fio – clique para saber mais)

 

M-A | Uso de tocilizumabe e sarilumabe isoladamente ou em combinação com corticosteroides para Covid-19.

3 Mar, 2022 | 16:44h

Use of tocilizumab and sarilumab alone or in combination with corticosteroids for covid-19: systematic review and network meta-analysis – BMJ Medicine

Editorial: Treatment of severe covid-19 with interleukin 6 receptor inhibition – BMJ Medicine

Estudo relacionado (publicado recentemente): Mortality Rates Among Hospitalized Patients With COVID-19 Infection Treated With Tocilizumab and Corticosteroids: A Bayesian Reanalysis of a Previous Meta-analysis – JAMA Network Open

COVID-19 em pessoas com doenças reumáticas: riscos, desfechos e considerações de tratamento.

3 Mar, 2022 | 16:41h

COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations – Nature Reviews Rheumatology

 

Comentário no Twitter

 

Miocardite após vacinação com BNT162b2 contra COVID-19 entre adolescentes em Hong Kong.

3 Mar, 2022 | 16:38h

Myocarditis Following COVID-19 BNT162b2 Vaccination Among Adolescents in Hong Kong – JAMA Pediatrics

Comentário: Study: Dosing change could reduce COVID-19 vaccine heart side effect in teens – UPI

Conteúdos relacionados:

[Preprint] Post-marketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12-39 years in Italy.

Myocarditis after BNT162b2 vaccination in Israeli adolescents.

Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021.

A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine.

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.